Quick Answer
Polycystic Ovary Syndrome (PCOS) has officially been renamed to Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change was announced on May 12, 2026, following a landmark consensus study published in The Lancet and a 14-year global campaign by patient advocates and endocrinologists.
The new name is designed to replace the misleading emphasis on "cysts" and better reflect the condition's true nature as a complex metabolic and hormonal disorder affecting roughly 1 in 8 women globally.
The short answer
Polycystic Ovary Syndrome (PCOS) has officially been renamed to Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change was announced on May 12, 2026, following a landmark consensus study published in The Lancet and a 14-year global campaign by patient advocates and endocrinologists.
The new name is designed to replace the misleading emphasis on "cysts" and better reflect the condition's true nature as a complex metabolic and hormonal disorder affecting roughly 1 in 8 women globally.
Why was the name PCOS considered misleading?
For decades, the term "polycystic" created a fundamental misunderstanding of the condition. Many patients diagnosed with PCOS do not actually have pathological ovarian cysts at all. The follicles often visible on ultrasounds are simply normal ovarian follicles that have not developed properly.
By framing the disease as primarily a gynecological issue centered on the ovaries, the old name caused a cascade of negative effects across the medical system. Up to 70% of affected individuals went undiagnosed because their symptoms did not perfectly align with having "cysts." Doctors and patients alike often overlooked the massive metabolic and cardiovascular risks associated with the condition because the name directed attention solely toward reproductive organs.
What does PMOS stand for?
The new name, Polyendocrine Metabolic Ovarian Syndrome, breaks down into three key components that accurately describe the multisystem nature of the disease:
- Polyendocrine: The complex hormonal fluctuations, including elevated androgens and insulin resistance, that drive the condition's symptoms across multiple body systems.
- Metabolic: The heavy impact on weight regulation, insulin sensitivity, and the significantly increased future risk of developing Type 2 diabetes and cardiovascular disease.
- Ovarian: The continued acknowledgment of reproductive and fertility challenges, but without making them the sole defining characteristic of a multisystem disorder.
This terminology shift directly acknowledges that PMOS is not simply a reproductive condition. It is a whole-body endocrine and metabolic syndrome with ovarian manifestations.
How will the transition to PMOS work?
Changing the name of a globally recognized disease does not happen overnight. The Endocrine Society and other international medical bodies have laid out a structured three-year transition plan to integrate the PMOS terminology into clinical practice.
The transition includes updating electronic health records, revising medical textbooks and educational materials, and launching public awareness campaigns to help patients understand the new terminology. The plan will culminate in an updated International Guideline scheduled for publication in 2028.
For patients currently diagnosed with PCOS, your medical records will gradually transition to the new terminology during routine care visits. The biological condition itself has not changed, only the name used to describe it.
What does this mean for patient care?
While the biological treatment methods for managing the condition remain the same, the name change is expected to significantly alter how doctors approach patient care. By removing the misleading "cyst" focus, PMOS encourages clinicians to evaluate and treat the metabolic and hormonal aspects of the disease much earlier in the patient journey.
Patients may find that general practitioners and endocrinologists are more likely to screen for insulin resistance, cardiovascular risk factors, and metabolic syndrome markers during initial consultations, rather than waiting until reproductive symptoms become the primary complaint.
The name change also promises to reduce some of the stigma surrounding fertility issues, as the condition will no longer be framed exclusively as an ovarian or reproductive problem.
Frequently asked questions
What is the new name for PCOS in 2026?
PCOS has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome, abbreviated as PMOS. The change was announced on May 12, 2026, following a consensus study in The Lancet.
Why was the name of PCOS changed?
The term "polycystic" was misleading because many patients do not actually have ovarian cysts. The new name, PMOS, better reflects that the condition is a complex metabolic and hormonal disorder, not just a gynecological one.
Does PMOS change how the condition is treated?
The biological treatment methods remain the same, but the name change is designed to encourage earlier attention to metabolic and cardiovascular risk factors, rather than focusing primarily on reproductive symptoms.
The takeaway
The rename from PCOS to PMOS represents a significant step forward in how the medical community and the public understand this common condition. By accurately describing it as a polyendocrine and metabolic syndrome, the new name should lead to earlier diagnoses, more comprehensive care, and reduced stigma for the millions of women affected worldwide.
Disclaimer: This article reports on a medical terminology change for educational and informational purposes. It is not medical advice. Always consult a qualified healthcare provider for personal health concerns.
